Literature DB >> 17951208

Pathology of nonalcoholic fatty liver disease.

Matthew M Yeh1, Elizabeth M Brunt.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are gaining increasing recognition as components of the emerging epidemic of obesity in North America and in other parts of the world. These entities are considered the hepatic manifestations of the insulin resistance syndrome and represent the spectra of fatty liver disease associated with it. All features of metabolic syndrome are associated with NAFLD/NASH, including obesity, type 2 diabetes, arterial hypertension, and hyperlipidemia in the form of elevated triglyceride levels. NAFLD/NASH can progress to liver cirrhosis and has been reported as a cause of hepatocellular carcinoma. In this review, the histopathologic features of NAFLD/NASH and differential diagnostic considerations are discussed. In addition, grading and staging schema proposed and currently in use are reviewed. Finally, other aspects for consideration by practicing pathologists, such as sampling issues, histopathologic findings after therapeutic interventions, and recurrence after liver transplantation, are addressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951208     DOI: 10.1309/RTPM1PY6YGBL2G2R

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  101 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Sandra K Erickson
Journal:  J Lipid Res       Date:  2008-12-12       Impact factor: 5.922

Review 3.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 4.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

5.  Nimbolide attenuate the lipid accumulation, oxidative stress and antioxidant in primary hepatocytes.

Authors:  Ghedeir M Alshammari; Aristatile Balakrishnan; Thirunavukkarasu Chinnasamy
Journal:  Mol Biol Rep       Date:  2017-11-28       Impact factor: 2.316

6.  Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis.

Authors:  Naim Alkhouri; Anna Alisi; Vera Okwu; Ammar Matloob; Federica Ferrari; Annalisa Crudele; Rita De Vito; Rocio Lopez; Ariel E Feldstein; Valerio Nobili
Journal:  Dig Dis Sci       Date:  2015-03-13       Impact factor: 3.199

Review 7.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 8.  The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  Lipids Health Dis       Date:  2010-04-28       Impact factor: 3.876

9.  Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression.

Authors:  Jennifer L Estall; Mario Kahn; Marcus P Cooper; Ffolliott Martin Fisher; Michele K Wu; Dina Laznik; Lishu Qu; David E Cohen; Gerald I Shulman; Bruce M Spiegelman
Journal:  Diabetes       Date:  2009-04-14       Impact factor: 9.461

10.  Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance.

Authors:  Florian W Kiefer; Maximilian Zeyda; Karina Gollinger; Birgit Pfau; Angelika Neuhofer; Thomas Weichhart; Marcus D Säemann; René Geyeregger; Michaela Schlederer; Lukas Kenner; Thomas M Stulnig
Journal:  Diabetes       Date:  2010-01-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.